Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Lawson

Showing results (121-130 of 128) with videos related to

Pageof 13
Sort By:
You have reached the last page of results.This site can display upto 128 results.
Journal of Medicinal Chemistry|July 14, 2022
Design and Discovery of MRTX0902, a Potent, Selective, Brain-Penetrant, and Orally Bioavailable Inhibitor of the SOS1:KRAS Protein-Protein InteractionJohn M Ketcham, Jacob Haling, Shilpi Khare, et al.
Journal of Medicinal Chemistry|December 10, 2021
Identification of MRTX1133, a Noncovalent, Potent, and Selective KRAS<sup>G12D</sup> InhibitorXiaolun Wang, Shelley Allen, James F Blake, et al.
Nature Medicine|October 10, 2022
Anti-tumor efficacy of a potent and selective non-covalent KRAS<sup>G12D</sup> inhibitorJill Hallin, Vickie Bowcut, Andrew Calinisan, et al.
Nature Reviews. Clinical Oncology|August 29, 2013
The Society for Immunotherapy of Cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanomaHoward L Kaufman, John M Kirkwood, F Stephen Hodi, et al.
Journal of Medicinal Chemistry|March 13, 2024
Discovery of Pyridopyrimidinones that Selectively Inhibit the H1047R PI3Kα Mutant ProteinJohn M Ketcham, Stephen J Harwood, Ruth Aranda, et al.
Molecular Cancer Therapeutics|June 21, 2024
The SOS1 Inhibitor MRTX0902 Blocks KRAS Activation and Demonstrates Antitumor Activity in Cancers Dependent on KRAS Nucleotide LoadingNiranjan Sudhakar, Larry Yan, Fadia Qiryaqos, et al.
Cancer Discovery|August 8, 2023
MRTX1719 Is an MTA-Cooperative PRMT5 Inhibitor That Exhibits Synthetic Lethality in Preclinical Models and Patients with MTAP-Deleted CancerLars D Engstrom, Ruth Aranda, Laura Waters, et al.
The New England Journal of Medicine|June 23, 2021
Acquired Resistance to KRAS<sup>G12C</sup> Inhibition in CancerMark M Awad, Shengwu Liu, Igor I Rybkin, et al.
Pageof 13

Showing results (121-130 of 128) with videos related to

Sort By:
Pageof 13
You have reached the last page of results.This site can display upto 128 results.
Journal of Medicinal Chemistry|July 14, 2022
Design and Discovery of MRTX0902, a Potent, Selective, Brain-Penetrant, and Orally Bioavailable Inhibitor of the SOS1:KRAS Protein-Protein InteractionJohn M Ketcham, Jacob Haling, Shilpi Khare, et al.
Journal of Medicinal Chemistry|December 10, 2021
Identification of MRTX1133, a Noncovalent, Potent, and Selective KRAS<sup>G12D</sup> InhibitorXiaolun Wang, Shelley Allen, James F Blake, et al.
Nature Medicine|October 10, 2022
Anti-tumor efficacy of a potent and selective non-covalent KRAS<sup>G12D</sup> inhibitorJill Hallin, Vickie Bowcut, Andrew Calinisan, et al.
Nature Reviews. Clinical Oncology|August 29, 2013
The Society for Immunotherapy of Cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanomaHoward L Kaufman, John M Kirkwood, F Stephen Hodi, et al.
Journal of Medicinal Chemistry|March 13, 2024
Discovery of Pyridopyrimidinones that Selectively Inhibit the H1047R PI3Kα Mutant ProteinJohn M Ketcham, Stephen J Harwood, Ruth Aranda, et al.
Molecular Cancer Therapeutics|June 21, 2024
The SOS1 Inhibitor MRTX0902 Blocks KRAS Activation and Demonstrates Antitumor Activity in Cancers Dependent on KRAS Nucleotide LoadingNiranjan Sudhakar, Larry Yan, Fadia Qiryaqos, et al.
Cancer Discovery|August 8, 2023
MRTX1719 Is an MTA-Cooperative PRMT5 Inhibitor That Exhibits Synthetic Lethality in Preclinical Models and Patients with MTAP-Deleted CancerLars D Engstrom, Ruth Aranda, Laura Waters, et al.
The New England Journal of Medicine|June 23, 2021
Acquired Resistance to KRAS<sup>G12C</sup> Inhibition in CancerMark M Awad, Shengwu Liu, Igor I Rybkin, et al.
Pageof 13